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Increased thromboxane biosynthesis in childhood hemolytic uremic
syndrome. Vascular endothelial cell damage plays a central role in the
pathogenesis of the hemolytic uremic syndrome (HUS), resulting in
intravascular platelet activation and thrombotic microangiopathy. A
deficiency of the antiaggregatory prostacyclin (PGI2) has been postu-
lated by experiments under ex vivo conditions. However, this obser-
vation has not been confirmed in vivo. The pathophysiological contri-
bution of thromboxane (Tx)A2, a potent vasoconstrictor and platelet-
aggregating prostanoid which is predominantly produced by platelets,
has not been elucidated so far. In order to quantitate endogenous
formation of TxA2 in children with HUS, plasma concentrations of the
enzymatic metabolite 1 l-dehydro-TxB2 of TxA2 and urinary excretion
rates of three major TxA2 metabolites, TxB2, I l-dehydro-TxB2 and
2,3-dinor-TxB2 were analyzed using gas chromatography/mass spec-
trometry. PGI2 biosynthesis was assessed by measuring urinary excre-
tion of an index metabolite of its systemic production, 2,3-dinor-
6-keto-prostaglandin (P0) F,, and an index of its renal production,
6-keto-PGF1,,. TxA2 biosynthesis was markedly elevated in the acute
phase of HUS. This activation could be detected for a longer period of
time than the presence of thrombocytopenia. Concomitantly in the
acute phase, renal P012 formation was significantly elevated and
systemic PG!2 formation was elevated in 50% of the patients. These
data indicate that TxA2 formation is increased in the acute phase in
patients with HUS. This enhanced biosynthesis is consistent with
increased platelet activation, whereas the increased PG!2 biosynthesis
reflects predominantly renal endothelial cell damage.
Hemolytic uremic syndrome (HUS) is the major cause of
acute renal failure in infancy and childhood [1]. Despite its
frequency, the etiology and pathogenesis have not been com-
pletely elucidated. The disease process can be initiated by
various bacterial and viral toxins [2], inducing endothelial cell
damage in small renal and extrarenal arteries, arterioles and
capillaries [3]. The endothelial injury leads to a loss of throm-
bogenic inhibitory properties of the vessel wall resulting in
intravascular platelet activation [4, 5]. This increased platelet-
vessel wall interaction is likely to be associated with changes in
prostanoid biosynthesis at the platelet-vascular interface. The
endothelium produces prostacyclin (PGI2), a major arachido-
Received for publication June 20, 1989
and in revised form October 18, 1989
Accepted for publication October 30, 1989
© 1990 by the International Society of Nephrology
nate acid metabolite with potent vasodilative and antiaggrega-
tory properties. The deficiency of a plasma PG!2 stimulating
factor has been postulated in adult HUS patients as well as in
typical and atypical cases in childhood by experiments in which
the effect of HUS plasma on PG!2 production by rat aortic rings
was studied [6—8]. These data have been recently refuted [9],
presumably reflecting methodological problems of this ap-
proach. Despite broad evidence of in vivo platelet activation in
HUS, no reliable data have been published regarding the in vivo
formation of thromboxane (Tx)A2, a potent vasoconstrictor and
platelet-aggregating substance which is predominantly pro-
duced by platelets [10]. TxA2 itself is highly labile [11], being
rapidly degraded to its biologically-inactive hydration product
TxB2. A previous attempt to determine the pathophysiological
role of TxA2 in HUS used plasma immunoreactive TxB2
concentrations to assess endogenous TxA2 generation [12], but
this method is readily confounded by artifactual formation of
TxA2 by platelets ex vivo [13, 14].
In view of these conflicting results, we have sought to
determine the in vivo formation of TxA2 and PG!2 in patients
with HUS using sensitive and specific methods that bypass the
problems of artifactual alterations. TxA2 biosynthesis was
examined by measuring the two major urinary enzymatic
metabolites, 1 l-dehydro-TxB2 and 2,3-dinor-TxB2, which are
index metabolites of TxA2 activation in the systemic circulation
[15, 16], and by measuring urinary TxB2, which predominantly
reflects renal TxA2 formation [17]. Furthermore, TxA2 activity
was estimated by determination of plasma 1 l-dehydro-TxB2
levels, the most abundant enzymatic metabolite of TxB2 [18,
19]. The analysis of this compound, unlike plasma TxB2, avoids
the artifactual increase in TxA2 formation during blood sam-
pling [20]. In addition, PGI2 biosynthesis in patients with HUS
was assessed with use of a highly specific non-invasive method.
This is the measurement of its urinary metabolite 2,3-dinor-
6-keto-prostaglandin (PG)F1 as an index of systemic PGI2
formation [21] and measurement of 6-keto-PGF1, which is
derived predominantly from the kidney [22].
The aim of this study was to define the pathophysiological
role of vasoactive prostanoids in HUS. Evidence of an in-
creased TxA2-formation could provide a rational basis for
intervention with drugs that modify arachidonate metabolism in
this disease.
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Table 1. Clinical data of the study group
Patient
Age
years Prodrome
Duration of anuria
days
Extrarenal organ
manifestations Treatment Outcome
1 4 diarrhea — — PD complete recovery
2 7"/12 diarrhea 4 — HDITPE complete recovery
3 68/12 — somnolence, petechiae,
severe hypertension
HD/TPE chronic renal failure
4 3 diarrhea 35 hemiparesis, convulsions,
hemorrhagic colitis
PD chronic renal failure
5 310/12 diarrhea 9 hemorrhagic colitis — complete recovery
6 2"/12 diarrhea 9 — PD/TPE complete recovery
7 "/u diarrhea — hemorrhagic colitis PD/TPE complete recovery
8 5 10/12 respiratory infection — — — complete recovery
9 8/ diarrhea — — — complete recovery
10 1 diarrhea — — — complete recovery
Abbreviations are: PD, peritoneal dialysis; HD, hemodialysis; TPE, therapeutic plasma exchange.
Methods
Patients and study protocol
Ten children with HUS, five girls and five boys, admitted to
the University Children's Hospital between November 1986
and February 1988 were studied. The clinical data of the 10
patients are depicted in Table 1. The diagnosis of HUS was
based upon the triad of microangiopathic hemolytic anemia
with burr cells in the peripheral blood smear, thrombocytope-
nia, and acute renal failure. Patients with secondary HUS due
to septicemia, glomerulonephritis or vasculitis were excluded.
No patient had received any drug known to interfere with
arachidonate metabolism within 14 days prior to entry into the
study. Eight patients had a diarrheal prodrome and are classi-
fied as typical cases [23]. One patient had an antecedent
respiratory infection, and one patient did not manifest any
prodromal symptoms (patient 3, Table 1). The latter patient had
an atypical HUS with insidious onset, petechiae and severe
hypertension. Only in patient three renal biopsy was done
which showed lesions classified as glomerular and arteriolar
thrombotic microangiopathy (mixed GIA type) [24]. All patients
entered the study within the first seven days after the presumed
onset of their disease.
Four children showed a mild clinical course, requiring only
conservative treatment, whereas the remaining six patients
required treatment with peritoneal dialysis (N = 4) or hemodi-
alysis (N = 2). Four of the latter patients underwent therapeutic
plasma exchange with a 5% albumin solution in addition. No
patient received infusions of fresh-frozen plasma.
Study protocol
In nine patients 3 ml of heparinized blood were drawn for
determination of plasma I l-dehydro-TxB2 at entry into the
hospital. These samples were taken serially every third day. In
eight non-anuric patients, urine was collected over 12 to 24
hours following admission to the study until discharge from the
hospital. Urine output was determined and aliquots stored at
—80°C for analysis of urinary prostanoids and creatinine. As
part of routine clinical care, blood was drawn at the end of each
urinary collection period for determination of thrombocytes,
creatinine and plasma 1 l-dehydro-TxB2. From these data the
creatinine clearance was calculated. Informed consent was
obtained from each child's parent(s) before the patients were
entered in the study. The protocol of this study was approved
by the Ethics Committee of the University of Heidelberg.
Assessment of prostanoid activity
For the analysis of urinary prostanoids, only gas chromato-
graphic mass spectrometric methods were used that have been
described previously [25—29]. Following the principle of stable
isotope dilution assays, endogenous prostanoids were quanti-
tated against their respective tetradeuterated analogues that
were added as internal standards at the beginning of the
procedure. The determination of 6-keto-PGF1 involved extrac-
tion by octadecyl silica and normal phase silica cartridges,
purification by high performance liquid chromatography, de-
rivatization to the methylester methoxime trimethylsilylethers,
and quantitation by capillary gas chromatography mass spec-
trometry in the electron impact mode 125, 26]. 2,3-dinor-
6-keto-PGF1 was purified by extraction and backextraction
under alkaline and acidic conditions and by thin-layer chroma-
tography. The pentafluorobenzylester methoxime trimethylsilyl-
ether derivative was analyzed by gas chromatography mass
spectrometry in the negative ion chemical ionization mode [27].
2,3-dinor-TxB2 and TxB2 were extracted chemoselectively by
phenylboronic acid columns, purified by thin-layer chromatog-
raphy and derivatized and quantitated in analogy to 2,3-dinor-
6-keto-PGF1 [28]. 1 1-dehydro-TxB2 was extracted from urine
and plasma by octadecyl silica cartridges, purified by thin-layer
chromatography, and analyzed as the pentafluorobenzylester
trimethylsilylether by gas chromatography-tandem mass spec-
trometry as described previously [29]. Prostanoid excretion
rates were expressed as ng/hr/l .73 m2 using Haycock's height-
weight formula for determination of body surface area [30]. The
normal range (10th to 90th percentile) of prostanoid excretion
was defined in healthy infants and children using the methods
described above. Analysis of creatinine in serum and urine were
performed by routine laboratory methods.
To assess the influence of renal function on the urinary
excretion rates of prostanoids, the excretion rates of TxB2,
I 1-dehydro-TxB2, 2,3-dinor-TxB2, 6-keto-PGF1a and 2,3-dinor-
6-keto-PGF1 were measured in 9 to 20 controls in different
stages of renal function. A significant correlation was found
between GFR assessed by endogenous creatinine clearance and
the excretion rate of all five prostanoid metabolites (Table 2). In
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Table 2. Correlation of urinary prostanoid excretion rates versus
glomerular filtration rate assessed by creatinine clearance in controls
with different stages of renal function
Variable Correlation
ll-dehydro-TxB2 r = 0.75; P < 0.05 N = 9
2,3-dinor-TxB, r = 0.72; P < 0.005 N = 20
TxB2 r=0.63;P<0.05 N=9
2,3-dinor-6-keto-PGF1,, r = 0.71; P < 0.005 N = 20
6-keto-PGF1 r = 0.69; P < 0.05 N = 9
order to correct for the influence of different degrees of renal
failure on prostanoid excretion rates, we measured the creati-
nine clearance simultaneously and expressed the excretion
rates per 100 ml/min/1 .73 m2 of creatinine clearance.
To avoid assumptions with regard to distribution of data,
groups were compared by Wilcoxon's rank sum test. The
relationship between prostanoid excretion and renal function
was examined by linear regression analysis. P < 0.05 was
accepted as statistically significant.
Results
Urinary excretion rates of the three TxA, metabolites were
elevated in the acute phase of HUS (Fig. I). Urinary TxB7
secretion rates were increased in six out of eight patients in the
acute phase (P < 0.05) and returned towards normal in the
postacute phase. The highest value in the postacute phase
showed patient 3 with atypical HUS who developed chronic
renal failure. Elevated levels of 2,3-dinor-TxB2 were measured
in the acute phase in seven out of eight patients (P < 0.05).
Values fell towards baseline levels in the postacute phase. A
similar pattern was obtained for the urinary excretion rate of the
second major index metabolite of systemic thromboxane acti-
vation, ll-dehydro-TxB,. Six out of eight patients showed an
increased excretion rate in the acute phase (P < 0.05). Levels
returned within the normal range in the postacute phase.
Urinary excretion of 2,3-dinor-TxB2 and 1 1-dehydro-TxB2 in
the acute phase was positively correlated (r = 0.94, P < 0.01).
The two patients showing no increase in urinary TxA2 metab-
olites had a mild clinical course. A concomitant increase in the
plasma 11-dehydro-TxB, levels were noted (P < 0.02) in the
majority of patients (Fig. 2). In summary, with one exception,
the peak levels of TxA2 metabolites in the acute phase of HUS
exceeded the upper 90 per cent confidence limit for that of a
control group of normal infants and children and uremic pa-
tients.
To determine the duration of TxA, activation during the
disease process, plasma and urine metabolites were analyzed
serially as outlined above. Enhanced TxA2 biosynthesis was
detected for a longer period of time (median 12 days, range 6 to
21) than the presence of thrombocytopenia (median 5 days,
range 3 to 17; P < 0.05).
The increased TxA, formation was associated with an en-
hanced endogenous biosynthesis of PG!, (Fig. 3). Urinary
6-keto-PGF1 excretion was significantly elevated in the acute
phase (P < 0.05) and urinary 2,3-dinor-6-keto-PGF1,, levels
were increased in four of eight patients. In the postacute phase
the levels were usually in the normal range, with the exception
of patient 3 with atypical HUS who showed decreased 2,3-
dinor-6-keto PGF1 values in the postacute phase. The clinical
course of this patient is depicted in Figure 4. Elevated TxA2
metabolites in plasma and urine could be detected in the acute
phase. Concomitantly, the 2,3-dinor-6-keto-PGF1 excretion
rate was increased. Normalization of the platelet count was
associated with a fall in TxA2 biosynthesis which, however,
remained elevated, reflecting continued platelet activation dur-
ing this period. A relapse with increased hemolytic activity
indicated by a rise in LDH values occurred concomitant with a
second increase in TxA2 formation. In contrast, the time course
of a patient with typical HUS and a favorable outcome is shown
in Figure 5. TxA2 metabolites were increased in the acute
phase, and remained elevated for some time even after normal-
ization of the platelet count. Initial PGI2 biosynthesis was also
significantly increased. In the postacute phase, characterized
by normal renal function, excretion rates of TxA2 and PGI2
metabolites returned to the normal range.
Discussion
This study demonstrates increased TxA2 biosynthesis in
patients from both typical and atypical HUS during the acute
phase of the disease. In the postacute phase TxA2 formation
returned to normal values which were comparable to levels in a
uremic control group. In order to quantitate endogenous for-
mation of TxA2 we measured the urinary excretion of 2,3-
dinor-TxB2 and 11-dehydro-TxB,, the two major urinary
metabolites of TxB2. The urinary excretion of these two metab-
olites is a sensitive, non-invasive index of in vivo systemic
TxA1 formation [15, 16], while urinary excretion of TxB2
reflects predominantly renal TxA2 activity [17]. By combined
analysis of three metabolites, we could exclude the possibility
that the increased excretion of one metabolite reflects just a
preferential pathway of TxA2 metabolism in HUS and not an
actual increase in TxA2 formation. Endogenous urinary 11-
dehydro-TxB2 excretion rates exceeded those of endogenous
urinary 2,3-dinor-TxB2 in our patients with HUS. This is in
accordance with previous reports that 1 l-dehydro-TxB2 is a
more abundant urinary thromboxane metabolite than 2,3-dinor-
TxB2 in human urine in both healthy volunteers [19] and in
patients with severe atherosclerotic disease [16]. In addition,
plasma 1 l-dehydro-TxB2 was also elevated in the acute phase
of HUS. This demonstrates that elevated urinary metabolites
reflect an increased biosynthesis. Thus the elevated 11-dehy-
dro-TxB2 and 2,3-dinor-TxB2 levels in our patients with HUS
indicated enhanced TxA2 biosynthesis in vivo and not a conse-
quence of altered TxA7 metabolism or altered renal function.
Since thrombocytes are the major source of TxA2 in humans
[10], the increase in TxA2 formation in the patients with HUS
probably reflects platelet activation, whereas other sources
than thrombocytes such as vascular endothelium and mono-
cytes/macrophages may have contributed to a small extent to
enhanced thromboxane biosynthesis. This concept is consistent
with previous observations of platelet activation reported in the
literature: thrombocytopenia with megakaryocytic hyperplasia
seen in the bone marrow [31]; shortened platelet survival time
[32]; evidence for circulation of degranulated "exhausted"
platelets [4]; and reduced intraplatelet serotonin [5, 33]. In our
patients enhanced TxA, biosynthesis was detected for a longer
period of time than thrombocytopenia. This indicates persis-
tence of platelet activation despite normalization of the platelet
count. In patient 3, with an atypical course (Fig. 4) TxA2
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activation persisted for several weeks. During a relapse of HUS
a second increase of TxA2 biosynthesis was detected. These
observations are consistent with findings of Walters et al [5]
who observed reduced intraplatelet serotonin and increased
plasma levels of serotonin for several weeks and during succes-
sive relapses in some cases of HUS.
In a previous report by Stuart et al, TxA2 formation in
patients with HUS was studied [12]. However, the results are
inconclusive, since measurements of immunoreactive TxB2 in
plasma are readily confounded by ex vivo platelet activation
[13]. Even minor degrees of platelet activation during sampling
will induce formation of TxA2 and its non-enzymatic hydrolysis
to TxB2 [14]. The reported TxB2 plasma concentrations of the
control group in the study of Stuart et al [12] were an order of
magnitude higher than the maximal physiological concentra-
tions of endogenous TxB2 in plasma (1 to 2 pg/mI) which is
predicted by determination of urinary excretion rates of Tx
metabolites [341.
In addition to an enhanced TxA2 biosynthesis, the present
study demonstrated an increased in vivo PG!2 formation. This
prostanoid is the principal metabolite of arachidonic acid pro-
duced by vascular endothelium and has potent vasodilative and
platelet antiaggregatory effects [35, 36]. PG!2 is not a circulating
hormone in man [21, 37], but platelet-inhibitory concentrations
are formed locally after non-specific vascular injury to limit the
degree of platelet activation [38]. Our finding is consistent with
previous observations that endogenous PG!2 formation is in-
creased in patients with evidence of enhanced platelet-vessel
wall interaction, such as severe atherosclerosis [39], unstable
coronary disease [401, systemic sclerosis and Raynaud's phe-
nomenon [41]. Thus, increased PG!2 biosynthesis in HUS
probably reflects endothelial cell damage. The more pro-
nounced increase of the index metabolite of renal PG!2 forma-
tion is consistent with the concept that primarily the vascula-
ture of the kidneys is damaged in HUS. This is in accordance
with histological findings showing endothelial cell swelling and
separation of the endothelium from the glomerular basement
membrane [24] and with biochemical findings of increased
levels of high molecular weight von Willebrand factor multim-
ers as an indicator of endothelial cell damage [42]. Stuart et al
[121 have also tried to assess in vivo PG!2 concentrations in
HUS by measuring the immunoreactive hydrolysis product
6-keto-PGF1 in plasma; however, this approach is subject to
similar analytic artifacts as measuring TxB2 in plasma.
A number of reports have described a deficiency of a plasma
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Fig. 1. Urina,y excretion rates of TxB2, 2,3-dinor-
TxB2 and I1-dehydro-TxB2 during the acute and
postacute phase in patients with HUS. The
prostanoid excretion rates are expressed per 100 ml
creatinine clearance. Open symbols denote mild
cases (conservative treatment), the half closed
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the dotted lines represents the normal range (lOth—9Oth percentile).
Acute Postacute
1138 Tanshoffet a!: Increased thromboxane biosynthesis in HUS
Acute Postacute
phase
Fig. 3. Urinary excretion rates of6-keto-PGF,,, and
2,3-dinor-6-keto-PGF, in patients during the acute
and postacute phase of HUS. The prostanoid
excretion rates are expressed per 100 ml creatinine
clearance. For symbols see Fig. 1. The area between
the dotted lines represents the normal range.
Cre,mgIdi 6 °° LDH, lU/liter
0 -..0..0...cP
t.o 0
1 1dh-TxB2,,,,,
pg/mi
1500 750
I \ dinor-TxB2500 £ . -— 25O ng 100
20:
°° [h m X —]
50
dinor-6-keto-
PGF1
r ng '"i00125
thxl.73m2X Cci
0
_______ ____________
24 27 3032 40 60 80
A
80
60
40
20
0o
—
0
x0
B
80
60
40
20
-
D X
C') •c
P < 0.05
0
Acute Postacute
phase
relapse
200
100
0
Platelets,
x 103/mm3
1 1-dh-TxB2,,
I ng 100
lx 1.73m2 Ccr
-0--
40
20
0
60
TxB20,
I ng 1001
30[Ii x 1.73m2 cJ
-.-
0 :
Time, days
Fig. 4. Time course of patient 3 with
atypical HUS. Cr denotes creatinine,
LDH lactatdehydrogenase. Prostanoid
excretion rates are expressed per 100
ml creatinine clearance. The normal
ranges of the prostanoid excretion rates
are indicated by the area between the
dotted lines.
8Crem, mg/d/ f
-.-
4'.
200
11-dh-TXB2 I
I ng 1001 IX 100 F)< 1.73 m2 Cc,J
—.— I-
dinor-6-keto-
PGF1
f
ng
h x 1.73m2 CcrJ
Tonshoffet a!: Increased thromboxane biosynthesis in HUS 1139
PG!, stimulating factor in adults [6] as well as in children with
atypical HUS, whereas it was found to be normal in most cases
with a typical form [81. However, a recently published study
reported normal PG!2 stimulating activity in all children studied
[9]. In assessing these conflicting data, one should keep in mind
that these test systems measured an ex vivo PG!2 stimulating
activity by incubating plasma from patients with HUS in vitro
with rat aortic rings. This approach does not provide any
information about the actual biologically effective activity of
PG!2 in vivo. In contrast, in the present study the in vivo PG!2
biosynthesis was increased in the acute phase of HUS. How-
ever, the data obtained in vitro and in vivo are not necessarily
contradictory, since a reduced PG!2 stimulating activity may be
a result of in vivo consumption in an attempt of the organism to
maintain increased local PG!2 levels as the report of Stuart et al
[12] has noted. Our finding in one patient with atypical relapsing
HUS showing increased PG!2 biosynthesis in the acute phase
and decreased formation in the follow-up phase (Fig, 4), is
consistent with this concept.
The functional importance of increased TxA2 formation and
TxA2-mediated platelet activation in HUS is unknown. One
uncontrolled study using a high dose of aspirin (60 mg/kg) in
combination with dipyridamole in patients with HUS gave
inconclusive results [43]; however, the beneficial effect of TxA2
inhibition could have been limited by the concurrent inhibition
of PG!2 biosynthesis. One controlled study using dipyridamol
alone as an antiplatelet drug in combination with heparin did not
show any benefit from this treatment over symptomatic therapy
[44]. However, dipyridamole is a weak antiplatelet drug without
any demonstrable effect on TxA2 biosynthesis [45]. In addition,
dipyridamole was discontinued in this study at normalization of
the platelet count, whereas the present study and that of
Walters et al [5] have demonstrated platelet activation beyond
the phase of thrombocytopenia. In thrombotic thrombocy-
topenic purpura, a disorder closely related to HUS [46], anti-
platelet therapy with aspirin/dipyridamol is generally recom-
mended early in the course of the disease [47]. Controlled
studies, however, are similarly lacking. In a rat model of
endotoxin-induced acute renal failure, which shares some as-
pects with HUS, administration of a selective TxA2 synthetase
inhibitor prevented the fall in renal plasma flow and significantly
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Fig. 5. Time course of patient one with
typical HUS. Cr denotes creatinine, LHD
lactatdehydrogenase. Prostanoid excretion
rates are expressed per 100 ml creatinine
clearance. The normal ranges of the
prostanoid excretion rates are indicated by the
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preserved glomerular filtration rate [48], but the relation of this
animal model to HUS remains to be established.
In conclusion, this study demonstrated an enhanced TxA2
biosynthesis in the acute phase of HUS. The increase in TxA2
formation is consistent with platelet activation during the dis-
ease process. The increased PGI2 biosynthesis reflects endo-
thelial cell damage and may be to some extent a response of
vascular endothelium to limit the degree of platelet activation.
The functional significance of this finding can only be assessed
by a controlled therapeutic trial with selective inhibition of
TxA2 activity, such as, low dose aspirin, TxA2 synthesis
inhibitors, and TxA2 receptor antagonists, thereby preserving
PGI2 formation.
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